# Modulation of gut microbiota and metabolic profiles by Astragaloside IV in a chronic enteritis model

**Authors:** Jian-xia Liu, Yue-hong Xu, Si-di Li, Yong-fang Zhang, Jia-chuan Yang, Run-li He

PMC · DOI: 10.3389/fcimb.2026.1645113 · Frontiers in Cellular and Infection Microbiology · 2026-03-11

## TL;DR

Astragaloside IV, a Chinese herbal medicine, reduces chronic intestinal inflammation by improving gut bacteria and metabolism.

## Contribution

The study reveals how Astragaloside IV modulates gut microbiota and bile acid metabolism to treat chronic enteritis.

## Key findings

- Astragaloside IV reduces inflammation and improves symptoms in a chronic enteritis model.
- It increases beneficial gut bacteria and decreases harmful bacteria.
- AS-IV modulates bile acid biosynthesis to mitigate disease progression.

## Abstract

Chronic intestinal inflammatory diseases like ulcerative colitis severely impact millions globally. Current treatments using drugs manage inflammation short-term but have significant side effects and don’t address underlying issues like mucosal barrier repair. New treatments are needed, and Chinese herbal medicine is gaining attention for its low cost and side effects. This study used a DSS-induced chronic enteritis animal model and treated it with Astragaloside IV(AS-IV), a traditional Chinese medicine. 16S sequencing and LC-MS analysis showed that AS-IV significantly reduces DSS-induced inflammation. This encompasses an enhancement in body weight, a reduction in the bleeding index, diarrhea index, and disease activity index (DAI). Furthermore, AS-IV has the capacity to modulate gut microbiota diversity, augment the abundance of beneficial bacteria, diminish the prevalence of harmful bacteria, and mitigate disease progression through alterations in metabolic profiles. Integrated omics analysis has revealed that AS-IV can attenuate disease progression by modulating the biosynthesis of primary bile acids. In summary, this study showed that AS-IV significantly protects against chronic enteritis, as demonstrated by a DSS-induced colitis model. It explored the mechanisms involving gut microbiota and its metabolites, highlighting a new understanding of AS-IV’s pharmacological effects and the crucial role of gut microbiota in enhancing the anti-inflammatory properties of traditional Chinese medicine monomers.

## Linked entities

- **Chemicals:** Astragaloside IV (PubChem CID 158694), DSS (PubChem CID 23673837)
- **Diseases:** ulcerative colitis (MONDO:0005101)

## Full-text entities

- **Diseases:** inflammation (MESH:D007249), diarrhea (MESH:D003967), enteritis (MESH:D004751), colitis (MESH:D003092), Chronic intestinal inflammatory diseases (MESH:D007410), ulcerative colitis (MESH:D003093), bleeding (MESH:D006470)
- **Chemicals:** Astragaloside IV (MESH:C052064), bile acids (MESH:D001647), AS-IV (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013420/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013420/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013420/full.md

---
Source: https://tomesphere.com/paper/PMC13013420